An open-label, randomized, single dose, three-way crossover, six sequence pilot study to evaluate the relative bioavailability of one amlodipine 10 mg tablet and rosuvastatin 20 mg tablet to two fixed dose combination tablet formulations of amlodipine (10 mg) and rosuvastatin (20 mg) in healthy adult male and female subjects under fasting conditions

Trial Profile

An open-label, randomized, single dose, three-way crossover, six sequence pilot study to evaluate the relative bioavailability of one amlodipine 10 mg tablet and rosuvastatin 20 mg tablet to two fixed dose combination tablet formulations of amlodipine (10 mg) and rosuvastatin (20 mg) in healthy adult male and female subjects under fasting conditions

Completed
Phase of Trial: Phase I

Latest Information Update: 16 May 2017

At a glance

  • Drugs Amlodipine/rosuvastatin (Primary) ; Amlodipine; Rosuvastatin
  • Indications Hypertension
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 01 Mar 2016 Results published in the Clinical Pharmacology in Drug Development.
    • 25 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 13 Jun 2014 Planned End Date changed from 1 Jun 2014 to 1 Jul 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top